drugset
drugset / Trial / NCT04975711

Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers

NCT04975711 ↗

Phase 1 Completed 48 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

A Phase 1 Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers

Timeline

Start
2021-07-12
Primary completion
2021-11-03
Completion
2021-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HIP2105 Unknown — —
Subject RLD2104 Unknown — —

Indications

No indication recorded.